Dalpiciclib in HR+/HER2- ABC

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

NCT05586841 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

NCT06344780 ·Status: ACTIVE_NOT_RECRUITING

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

NCT07285382 ·Status: RECRUITING ·Phase: PHASE2

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

NCT07117630 ·Status: RECRUITING ·Phase: PHASE2

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

NCT05431504 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy

NCT05979220 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Dalpiciclib Plus Letrozole and Capecitabine

NCT05469750 ·Status: UNKNOWN ·Phase: PHASE2

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

NCT06149130 ·Status: RECRUITING ·Phase: PHASE2

A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer

NCT05628870 ·Status: RECRUITING ·Phase: PHASE1

Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer

NCT06637150 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer

NCT06599216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study

NCT06495515 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

NCT07037199 ·Status: RECRUITING ·Phase: PHASE2

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

NCT03772353 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

NCT06810492 ·Status: NOT_YET_RECRUITING ·Phase: NA

Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

NCT04997798 ·Status: UNKNOWN ·Phase: PHASE2

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

NCT05969184 ·Status: UNKNOWN ·Phase: PHASE2

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

NCT06107673 ·Status: RECRUITING ·Phase: PHASE2

RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody

NCT06481553 ·Status: ACTIVE_NOT_RECRUITING

An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

NCT06605690 ·Status: NOT_YET_RECRUITING ·Phase: NA

An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer

NCT06613373 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer

NCT07014410 ·Status: RECRUITING ·Phase: PHASE2

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

NCT06612814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

NCT05806671 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

NCT07207070 ·Status: RECRUITING ·Phase: PHASE3